Stocks Health care FLGT
NASDAQ · Health careFulgent Genetics, Inc. (FLGT)
Fulgent Genetics, Inc. brought in $330.3M of revenue over the twelve months to September 30, 2026, up 4.7% from a year earlier. It posted a net loss of $90.9M. In fiscal 2025 capital spending exceeded operating cash flow by $124.2M. At September 30, 2026 it held $86.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Fulgent Genetics, Inc.
- Net worth
- Fulgent Genetics, Inc. has a market value (market cap) of $709.3M at the latest share price, and shareholders' equity of $990.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $322.7M (+13.8% year on year), with a net loss of $60.5M. Over the 12 months to September 30, 2026: revenue $330.3M, net loss $90.9M.
- Cash flow
- In fiscal 2025 operations used $101.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Fulgent Genetics, Inc.'s next report is expected around February 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Fulgent Genetics, Inc. does
Fulgent Genetics, Inc. is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker FLGT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $322.7M | -$60.5M | n/a | -$124.2M |
| 2024 | $283.5M | -$42.7M | n/a | -$19.3M |
| 2023 | $289.2M | -$167.8M | n/a | $4.8M |
| 2022 | $619M | $143.4M | n/a | $234.7M |
| 2021 | $992.6M | $507.4M | n/a | $514.8M |
| 2020 | $421.7M | $214.3M | n/a | $105.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where FLGT ranks in Health care
Latest SEC filings
What Fulgent Genetics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 7.5% to $90.4M versus the same quarter last year; net loss of $13.2M.
- November 5, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 4.4% to $85.4M versus the same quarter last year; net loss of $29.5M.
- July 30, 2026
- June 2, 2026Other event 8-K
- May 27, 2026Activist stake changed SCHEDULE 13D/A
- May 21, 2026Other event 8-K
- May 14, 2026
- May 14, 2026
- May 1, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 3.2% to $71.1M versus the same quarter last year; net loss of $24.8M.
Insider trades
What the people running Fulgent Genetics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $117.1K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 26, 2026 | Kim PaulCFO and Treasurer | Shares withheld for tax | 2,748 | $55.6K |
| October 26, 2026 | Xie JianPresident and COO | Shares withheld for tax | 4,361 | $88.2K |
| October 26, 2026 | Gao HanlinChief Scientific Officer | Shares withheld for tax | 1,645 | $33.3K |
| September 2, 2026 | Gao HanlinChief Scientific Officer | Sold | 1,673 | $32.9K |
| September 2, 2026 | Xie JianPresident and COO | Sold | 2,127 | $41.8K |
| September 1, 2026 | Kim PaulCFO and Treasurer | Shares withheld for tax | 2,087 | $40.9K |
| September 1, 2026 | Hsieh MingChief Executive Officer, Director, 10% owner | Shares withheld for tax | 4,392 | $86K |
| August 27, 2026 | Gao HanlinChief Scientific Officer | Sold | 939 | $18.7K |
Who owns FLGT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ming Hsieh13D, may seek influence with 1 related filers | 32.26% | May 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 142 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 2,286,669 | -487,850 |
| Vanguard Capital Management LLC | 789,498 | -90,652 |
| Jacobs Levy Equity Management, Inc | 782,116 | +425,757 |
| Jpmorgan Chase & Co | 756,558 | +296,195 |
| Diametric Capital, LP | 697,784 | +336,738 |
| Ameriprise Financial Inc | 670,084 | +106,709 |
| Dimensional Fund Advisors LP | 625,355 | -46,309 |
| Geode Capital Management, LLC | 521,014 | -63,193 |
| State Street Corp | 498,673 | -30,726 |
| Invenomic Capital Management LP | 498,287 | -112,031 |
| Two Sigma Investments, LP | 400,986 | +78,797 |
| Charles Schwab Investment Management Inc | 350,987 | -3,197 |
| Millennium Management LLC | 320,910 | -80,909 |
| Goldman Sachs Group Inc | 307,940 | -3,483 |
| D. E. Shaw & Co., Inc. | 292,006 | -194,764 |
| Peapod Lane Capital LLC | 224,207 | +3,580 |
| Point72 Asset Management, L.P. | 211,708 | new |
| Medina Value Partners, LLC | 193,061 | +22,992 |
| Vanguard Portfolio Management LLC | 186,311 | -29,543 |
| Bank of America Corp | 175,581 | +54,998 |
Insiders
7 insiders reported holding 2,671,217 shares in total, about $68.9M at the last price.
| Holder | Shares |
|---|---|
| Gao HanlinChief Scientific Officer | 984,472 |
| Hsieh MingChief Executive Officer, Director, 10% owner | 885,952 |
| Xie JianPresident and COO | 355,563 |
| Kim PaulCFO and Treasurer | 353,795 |
| Dong LindaDirector | 38,758 |
| Groves Regina EDirector | 28,099 |
| Nohaile MichaelDirector | 24,578 |
Questions about FLGT
What does Fulgent Genetics, Inc. do?
Fulgent Genetics, Inc. is a company in the Health care sector, listed on NASDAQ as FLGT. Its shares trade on NASDAQ under the ticker FLGT.
What is Fulgent Genetics, Inc.'s net worth?
Fulgent Genetics, Inc. has a market value (market cap) of $709.3M at the latest share price, and shareholders' equity of $990.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Fulgent Genetics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $90.9M on revenue of $330.3M.
How much revenue does Fulgent Genetics, Inc. make?
Over the twelve months to September 30, 2026 Fulgent Genetics, Inc. reported revenue of $330.3M. That is 4.7% more than a year earlier.
When did Fulgent Genetics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Fulgent Genetics, Inc.'s next earnings report?
Fulgent Genetics, Inc.'s next report is expected around February 26, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare FLGT with
Follow FLGT
Get an email when Fulgent Genetics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Fulgent Genetics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.